Miles Gerson

Managing Officer of Business Development
University of California at Los Angeles

Miles Gerson joined UCLA's Office of Intellectual Property and Industry Sponsored Research in 2012 as the Managing Officer of Business Development. In this role, he serves as public representative for the Office, helping to promote UCLA intellectual property, identify potential industry sponsors, and expand licensing, spin-out & entrepreneurial activity at UCLA. Prior to UCLA, Miles helped to launch Surefire Medical Inc., a medical device company in Colorado, and served as an analyst for multiple investment firms including, High Country Venture, the CSU Management Fund, a venture fund for emerging research at Colorado State University, and Dag Dvergsten AS, a private equity/venture firm based in Oslo, Norway. Miles holds a JD/MBA from the University of Wisconsin, Madison, where he specialized in strategic management in life and engineering sciences, and worked with WARF to help guide the commercialization of academic research. Miles also holds a Bachelors and Masters degree in Neuroscience from Wesleyan University.

Check out the incredible speaker line-up to see who will be joining Miles.

Download The Latest Agenda

Day 3

Tuesday, May 10th, 2016

08:50 Chairperson’s Opening Address

09:35 PANEL: Best Practices For Alternative M&A Financing, Including Structured And Contingent Value Right (CVR) Transactions

• With the trend over the last couple years towards moving away from traditional M&A, what other transactions are surfacing and working well?

• Explaining the deal framework of a CVR transaction

• Exploring how CVRs have been designed and negotiated between the buy side and the sell side, including what achievement milestones have been put in place

• Exploring a consultant’s role in arranging CVR agreements and how they have seen them shift over the last year or two

11:00 PANEL: Exploring Opportunities In Converging Drug-Device Technologies And Their Place In BioPharma Future

• Examining the current state of drug-device combination products and how the technology, regulatory processes, and purchasers are coming together

• Are drug-device combos rarities or are they truly the wave of the future? The commonality of emerging biologic-device combination and solutions

• Uncovering how the industry will need to shift to support drug-device convergence technologies and what biopharma can do to enable this innovation

• Stories from the trenches: from customer selection and staffing the organization, to building your team and how best to approach the buying universe when its time to sell

o Selection of proprietary vs. off-the-shelf solutions vs. combinations

11:40 PANEL: Examining The Changing Face Of Venture Capital

• How has traditional venture capital changed over the past year, and what are expectations for the near- and far-term future?

• Exploring the emergence of venture capital groups associated with large provider organizations; what are their objectives in the current biopharma space?

• Discovering how the relationship between large pharma and VC is evolving